/LXEO
LXEO Stock - Lexeo Therapeutics, Inc. Common Stock
Healthcare|BiotechnologyNASDAQ
$10.35+3.92%
+$0.39 (+3.92%) • Dec 19
80
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.BUY
High Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.100
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).100
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.49
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+92.1%upside
Target: $19.88
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for LXEO
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$10.25 – $10.45
TARGET (TP)$19.88
STOP LOSS$9.52
RISK/REWARD1:11.5
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta1.78
52W High$10.79
52W Low$1.45
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | N/A | N/A | $654,000 | $1.66M | $518,476 |
| Gross Profit | N/A | N/A | $654,000 | $1.66M | $518,476 |
| Gross Margin | N/A | N/A | 100.0% | 100.0% | 100.0% |
| Operating Income | $-105,766,000 | $-68,513,000 | $-60,509,000 | $-50,637,000 | $-4,587,788 |
| Net Income | $-98,333,000 | $-66,394,000 | $-59,277,000 | $-50,622,000 | $-5,152,788 |
| Net Margin | N/A | N/A | -9063.8% | -3055.0% | -993.8% |
| EPS | $-3.09 | $-2.49 | $-2.36 | $-2.01 | $-0.20 |
Company Overview
Lexeo Therapeutics, Inc. operates as a clinical-stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich's ataxia (FA) cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate for the treatment of arrhythmogenic cardiomyopathy; LX2021, a gene therapy candidate for the treatment of DSP cardiomyopathy associated with it; and LX2022, a gene therapy candidate for the treatment of HCM caused by TNNI3 mutations. It also develops LX1001, an AAVrh10-based gene therapy candidate for the treatment of APOE4 homozygous; LX1020, a gene therapy candidate for the treatment of APOE4 homozygous; LX1021 for the treatment of APOE4 homozygotes; and LX1004 for the treatment of CLN2 Batten disease. The company was incorporated in 2017 and is based in New York, New York.
Visit WebsiteRating Distribution
Strong Buy
1
11%
Buy / Outperform
8
89%
Hold / Neutral
0%
Sell / Underperform
0%
Analyst Consensus🟢 Bullish
9 Bullish0 Neutral/Bearish
Price Targets
$23
Average Target
↑ 117.8% Upside
Now
$19
Low
$23
Average
$30
High
Based on 11 analysts
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| December 18th 2025 | Raymond James | Initiation | Strong Buy | $25 |
| November 20th 2025 | Cantor Fitzgerald | Initiation | Overweight | $19 |
| October 15th 2025 | Guggenheim | Initiation | Buy | $30 |
| July 31st 2025 | Oppenheimer | Initiation | Outperform | $20 |
| June 13th 2024 | Robert W. Baird | Initiation | Outperform | $28 |
| June 6th 2024 | H.C. Wainwright | Initiation | Buy | $22 |
| November 28th 2023 | JP Morgan | Initiation | Overweight | $20 |
| November 28th 2023 | Stifel | Initiation | Buy | $20 |
| November 28th 2023 | RBC Capital Mkts | Initiation | Outperform | $22 |
| November 28th 2023 | Leerink Partners | Initiation | Outperform | $19 |
| November 28th 2023 | Chardan Capital Markets | Initiation | Buy | $23 |
Earnings History & Surprises
LXEOBeat Rate
44%
Last 9 quarters
Avg Surprise
-44.3%
EPS vs Estimate
Beats / Misses
4/5
Last 12 quarters
Latest EPS
$-0.33
Q4 2025
EPS Surprise History
Q1 24
-16.4%
$-0.85vs$-0.73
Q2 24
-1.3%
$-0.77vs$-0.76
Q3 24
+7.2%
$-0.64vs$-0.69
Q4 24
-36.9%
$-0.89vs$-0.65
Q1 25
+10.3%
$-0.78vs$-0.87
Q2 25
-23.7%
$-0.99vs$-0.80
Q3 25
+6.3%
$-0.60vs$-0.64
Q4 25
+31.2%
$-0.33vs$-0.48
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q1 2026 | Mar 23, 2026 | $-0.33 | — | — | — |
Q4 2025 | Nov 5, 2025 | $-0.48 | $-0.33 | +31.2% | ✓ BEAT |
Q3 2025 | Aug 14, 2025 | $-0.64 | $-0.60 | +6.3% | ✓ BEAT |
Q2 2025 | May 12, 2025 | $-0.80 | $-0.99 | -23.7% | ✗ MISS |
Q1 2025 | Mar 24, 2025 | $-0.87 | $-0.78 | +10.3% | ✓ BEAT |
Q4 2024 | Nov 13, 2024 | $-0.65 | $-0.89 | -36.9% | ✗ MISS |
Q3 2024 | Aug 12, 2024 | $-0.69 | $-0.64 | +7.2% | ✓ BEAT |
Q2 2024 | May 9, 2024 | $-0.76 | $-0.77 | -1.3% | ✗ MISS |
Q1 2024 | Mar 11, 2024 | $-0.73 | $-0.85 | -16.4% | ✗ MISS |
Q4 2023 | Nov 6, 2023 | $-2.60 | $-12.36 | -375.4% | ✗ MISS |
Q2 2023 | Jun 30, 2023 | — | $-0.53 | — | — |
Q1 2023 | Mar 31, 2023 | — | $-0.74 | — | — |
Q4 2022 | Dec 31, 2022 | — | $-0.59 | — | — |
Q3 2022 | Sep 30, 2022 | — | $-0.68 | — | — |
Q2 2022 | Jun 30, 2022 | — | $-0.60 | — | — |
Q1 2022 | Mar 30, 2022 | — | $-0.47 | — | — |
Latest News
Lexeo Therapeutics shares are trading higher after Raymond James initiated coverage on the stock with a Strong Buy rating and announced a $25 price target.
📈 PositiveBenzinga•Dec 18, 2025, 02:13 PM
Raymond James Initiates Coverage On Lexeo Therapeutics with Strong Buy Rating, Announces Price Target of $25
📈 PositiveBenzinga•Dec 18, 2025, 09:46 AM
Chardan Capital Maintains Buy on Lexeo Therapeutics, Maintains $17 Price Target
📈 PositiveBenzinga•Dec 11, 2025, 12:19 PM
Cantor Fitzgerald Initiates Coverage On Lexeo Therapeutics with Overweight Rating, Announces Price Target of $19
📈 PositiveBenzinga•Dec 1, 2025, 01:58 PM
Cantor Fitzgerald Initiates Coverage On Lexeo Therapeutics with Overweight Rating, Announces Price Target of $19
📈 PositiveBenzinga•Nov 20, 2025, 11:58 AM
Chardan Capital Maintains Buy on Lexeo Therapeutics, Maintains $17 Price Target
📈 PositiveBenzinga•Nov 6, 2025, 12:18 AM
Lexeo Therapeutics Q3 EPS $(0.33) Beats $(0.54) Estimate
📈 PositiveBenzinga•Nov 5, 2025, 12:37 PM
HC Wainwright & Co. Maintains Buy on Lexeo Therapeutics, Lowers Price Target to $13
➖ NeutralBenzinga•Oct 21, 2025, 11:11 AM
Reported Earlier, Lexeo Therapeutics Prices $135M Public Offering Of 15.625M Shares At $8 Per Share And 1.25M Warrants At $7.9999 Each
➖ NeutralBenzinga•Oct 17, 2025, 05:50 AM
Lexeo Therapeutics shares are trading lower after the company announced a proposed public offering.
📉 NegativeBenzinga•Oct 16, 2025, 08:34 PM
Lexeo Therapeutics Announces Proposed Public Offering; Terms Not Disclosed
➖ NeutralBenzinga•Oct 16, 2025, 08:21 PM
Guggenheim Initiates Coverage On Lexeo Therapeutics with Buy Rating, Announces Price Target of $30
📈 PositiveBenzinga•Oct 15, 2025, 02:26 PM
Chardan Capital Maintains Buy on Lexeo Therapeutics, Raises Price Target to $17
📈 PositiveBenzinga•Oct 7, 2025, 05:56 PM
Lexeo climbs after regulatory update on Friedreich ataxia drug
📈 PositiveSeeking Alpha•Oct 7, 2025, 10:56 AM
Lexeo Therapeutics, FDA Feedback Opens Faster Path, Pivotal Study for Friedreich Ataxia Gene Therapy Could Shrink and Speed Up Approval
📈 PositiveBenzinga•Oct 7, 2025, 10:04 AM
Lexeo Therapeutics raises $80M in private placement
📈 PositiveSeeking Alpha•May 27, 2025, 05:56 PM
Frequently Asked Questions about LXEO
What is LXEO's current stock price?
Lexeo Therapeutics, Inc. Common Stock (LXEO) is currently trading at $10.35 per share. The stock has moved +3.92% today.
What is the analyst price target for LXEO?
The average analyst price target for LXEO is $19.88, based on 1 analyst.
What sector is Lexeo Therapeutics, Inc. Common Stock in?
Lexeo Therapeutics, Inc. Common Stock operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is LXEO's market cap?
Lexeo Therapeutics, Inc. Common Stock has a market capitalization of $0.76 billion, making it a small-cap company.
Does LXEO pay dividends?
No, Lexeo Therapeutics, Inc. Common Stock does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorAMRN
Amarin Corporation plc
$13.80
Mkt Cap: $0.3B
CAPR
Capricor Therapeutics, Inc.
$27.81
Mkt Cap: $1.3B
CTNM
Contineum Therapeutics, Inc. Class A Common Stock
$11.74
Mkt Cap: $0.3B
DBVT
DBV Technologies S.A.
$22.76
Mkt Cap: $0.5B
KYTX
Kyverna Therapeutics, Inc.
$7.19
Mkt Cap: $0.3B
LRMR
Larimar Therapeutics, Inc.
$3.65
Mkt Cap: $0.3B
MREO
Mereo BioPharma Group plc
$2.00
Mkt Cap: $0.3B
SLN
Silence Therapeutics plc
$6.37
Mkt Cap: $0.3B
VNDA
Vanda Pharmaceuticals Inc.
$6.75
Mkt Cap: $0.4B
VYGR
Voyager Therapeutics, Inc.
$4.00
Mkt Cap: $0.2B
Explore stocks similar to LXEO for comparison